Citius Pharmaceuticals, Inc. (CTXR) vs IN8bio, Inc. (INAB)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and IN8bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
INAB
IN8bio, Inc.
$1.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CTXR vs INAB
growth of $100 · dividends reinvested · last 5yCTXR -98.9% (-59.8%/yr)INAB -99.5% (-65.7%/yr)CTXR compounded faster over this window
CTXR INAB
CTXR vs INAB: by the numbers
- •INAB is the larger company ($13M vs $13M market cap).
- •Both run net losses; INAB's is the smaller (0.00% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CTXR | INAB |
|---|---|---|
| P/S ratio | 1.86 | N/A |
| P/B ratio | 0.20 | 0.73 |
Profitability
| Metric | CTXR | INAB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -651.27% | 0.00% |
| ROE | -69.47% | -101.66% |
| ROIC | -67.62% | -91.74% |
Growth (annualized)
| Metric | CTXR | INAB |
|---|---|---|
| Total return CAGR (5Y) | -60.04% | -62.88% |
Frequently asked
- How have CTXR and INAB total returns compared?
- Over the past 5 years, CTXR delivered -60.04% and INAB delivered -62.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.